Mepivacaine Hydrochloride

FDA Drug Profile — Mepivacaine, MEPIVACAINE HYDROCHLORIDE, Mepivacaine Hydrochloride, Carbocaine, Polocaine

Mepivacaine Hydrochloride is listed in the FDA National Drug Code directory with 12 NDC codes, marketed under brand names including Mepivacaine, MEPIVACAINE HYDROCHLORIDE, Mepivacaine Hydrochloride. Available dosage forms: injection, solution, powder.

Drug details

Generic Name
Mepivacaine Hydrochloride
Brand Names
Mepivacaine, MEPIVACAINE HYDROCHLORIDE, Mepivacaine Hydrochloride, Carbocaine, Polocaine, Scandonest 3% Plain
Application Number
ANDA088387
Sponsor
Novocol Pharmaceutical Of Canada, Inc.
NDC Codes
12
Dosage Forms
INJECTION, SOLUTION, POWDER
Routes
SUBMUCOSAL, SUBCUTANEOUS
Active Ingredients
MEPIVACAINE HYDROCHLORIDE

Indications and Usage

INDICATIONS AND USAGE: Mepivacaine is indicated for production of local anesthesia for dental procedures by infiltration or nerve block in adults and pediatric patients.

Warnings

WARNINGS: RESUSCITATIVE EQUIPMENT AND DRUGS SHOULD BE IMMEDIATELY AVAILABLE. (See ADVERSE REACTIONS ). Reactions resulting in fatality have occurred on rare occasions with the use of local anesthetics, even in the absence of a history of hypersensitivity. Fatalities may occur with use of local anesthetics in the head and neck region as the result of retrograde arterial flow to vital CNS areas even when maximum recommended doses are observed. The practitioner should be alert to early evidences of alteration in sensorium or vital signs. SCANDONEST ® 3% Plain is SULFITE FREE. Methemoglobinemia: Cases of methemoglobinemia have been reported in association with local anesthetic use; SCANDONEST ® , along with other local anesthetics, is capable of producing this condition. Although all patients are at risk for methemoglobinemia, patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, infants under 6 months of age, and concurrent exposure to oxidizing agents or their metabolites are more susceptible to developing clinical manifestations of the condition. If local anesthetics must be used in these patients, close monitoring for symptoms and signs of methemoglobinemia is recommended. Signs of methemoglobinemia may occur immediately or may be delayed some hours after exposure, and are characterized by cyanosis of the skin, nail beds and lips, and/or abnormal coloration of the blood, fatigue and weakness. Methemoglobin levels may continue to rise; therefore, immediate treatment is required to avert more serious central nervous system and cardiovascular adverse effects, including seizures, coma, arrhythmias, and death. Discontinue SCANDONEST ® and any other oxidizing agents. Depending on the severity of the signs and symptoms, patients may respond to supportive care, i.e., oxygen therapy, hydration. If methemoglobinemia does not respond to administration of oxygen, a more severe clinical presentation may require treatment with methylene blue, exchange transfusion, or hyperbaric oxygen.

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.